SNY Dec 2024 60.000 call
| Previous Close | 0.7500 |
| Open | 0.7500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 60.00 |
| Expire Date | 2024-12-20 |
| Day's Range | 0.7500 - 0.7500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
BloombergGSK Plunges as Drugmaker Must Face Zantac Cases in Delaware
(Bloomberg) -- GSK Plc shares plunged in the wake of a court ruling that the UK drugmaker, alongside others including Sanofi, must face trials over whether the former heartburn treatment Zantac causes cancer. Most Read from BloombergKey Engines of US Consumer Spending Are Losing Steam All at OnceHomebuyers Are Starting to Revolt Over Steep Prices Across USMnuchin Chases Wall Street Glory With His War Chest of Foreign MoneyNvidia Unveils Next-Generation Rubin AI Platform for 2026GameStop Shares D
ZacksFDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.
ZacksPharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.
